The plasminogen activation system in tumour invasion and metastasis

被引:41
作者
deVries, TJ
vanMuijen, GNP
Ruiter, DJ
机构
[1] Department of Pathology, University Hospital, Nijmegen
[2] Dept. of Pathology, University Hospital, NL-6500 HB Nijmegen
关键词
urokinase; plasminogen activator; histochemistry; prognostic factor;
D O I
10.1016/S0344-0338(96)80094-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The involvement of proteases in the metastatic spread of tumour cells and in tumour related processes, such as angiogenesis and ulceration, has been known for many decades. This chapter reviews the involvement of one proteolytic system - the plasminogen activation system - in tumour progression. In recent years, many biochemical properties of the various components of the plasminogen activation system have become known. These properties and the functional relationship between the components are discussed in the first section. Since interfering with proteolysis by tumour cells and by newly formed endothelial cells can be an objective for future therapy, experimental tumour models have been used to study the effects of inhibitors of plasminogen activation. The second section deals with this issue. Finally, the presence of the various components of the plasminogen activation system in human tumours is reviewed. Following the availability of specific ELISAs, antibodies and molecular probes, the content and the cellular distribution of the components of the plasminogen activation system have recently been mapped in various human tumours.
引用
收藏
页码:718 / 733
页数:16
相关论文
共 246 条
[1]  
ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
[2]   RECEPTOR-MEDIATED ENDOCYTOSIS OF PLASMINOGEN ACTIVATORS AND ACTIVATOR/INHIBITOR COMPLEXES [J].
ANDREASEN, PA ;
SOTTRUPJENSEN, L ;
KJOLLER, L ;
NYKJAER, A ;
MOESTRUP, SK ;
PETERSEN, CM ;
GLIEMANN, J .
FEBS LETTERS, 1994, 338 (03) :239-245
[3]   THE HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR - IDENTIFICATION OF A 420-KD CELL-SURFACE GLYCOPROTEIN SPECIFIC FOR THE ACTIVATED CONFORMATION OF ALPHA-2-MACROGLOBULIN [J].
ASHCOM, JD ;
TILLER, SE ;
DICKERSON, K ;
CRAVENS, JL ;
ARGRAVES, WS ;
STRICKLAND, DK .
JOURNAL OF CELL BIOLOGY, 1990, 110 (04) :1041-1048
[4]  
ASTEDT B, 1985, THROMB HAEMOSTASIS, V53, P122
[5]   INVIVO PATTERNS OF EXPRESSION OF UROKINASE AND ITS INHIBITOR PAI-1 SUGGEST A CONCERTED ROLE IN REGULATING PHYSIOLOGICAL ANGIOGENESIS [J].
BACHARACH, E ;
ITIN, A ;
KESHET, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10686-10690
[6]   CONFOCAL FLUORESCENCE MICROSCOPY OF UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR AND CATHEPSIN-D IN HUMAN MDA-MB-231 BREAST-CANCER CELLS MIGRATING IN RECONSTITUTED BASEMENT-MEMBRANE [J].
BASTHOLM, L ;
NIELSEN, MH ;
DEMEY, T ;
DANO, K ;
BRUNNER, N ;
HOYERHANSEN, C ;
RONNE, E ;
ELLING, F .
BIOTECHNIC & HISTOCHEMISTRY, 1994, 69 (02) :61-67
[7]  
BEHRENDT N, 1993, J BIOL CHEM, V268, P5985
[8]   FACULTATIVE POLYPEPTIDE TRANSLOCATION ALLOWS A SINGLE MESSENGER-RNA TO ENCODE THE SECRETED AND CYTOSOLIC FORMS OF PLASMINOGEN ACTIVATORS INHIBITOR-2 [J].
BELIN, D ;
WOHLWEND, A ;
SCHLEUNING, WD ;
KRUITHOF, EKO ;
VASSALLI, JD .
EMBO JOURNAL, 1989, 8 (11) :3287-3294
[9]   IMMUNOHISTOCHEMICAL LOCALIZATION OF THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN BREAST-CANCER [J].
BIANCHI, E ;
COHEN, RL ;
DAI, A ;
THOR, AT ;
SHUMAN, MA ;
SMITH, HS .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (05) :597-603
[10]  
BIANCHI E, 1994, CANCER RES, V54, P861